List of Figures
Figure 1: Estimated Hematologic Malignancies Cases
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Hematologic Malignancies Testing Market
Figure 3: Global Hematologic Malignancies Testing Market (by Product), $Million, 2021 and 2032
Figure 4: Global Hematologic Malignancies Testing Market (by Platform), $Million, 2021 and 2032
Figure 5: Global Hematologic Malignancies Testing Market (by Disease), $Million, 2021 and 2032
Figure 6: Global Hematologic Malignancies Testing Market (by End User), $Million, 2021 and 2032
Figure 7: Global Hematologic Malignancies Testing Market
Figure 8: Global Hematologic Malignancies Testing Market: Research Methodology
Figure 9: Primary Research Methodology
Figure 10: Bottom-Up Approach (Segment-Wise Analysis)
Figure 11: Global Hematologic Malignancies Testing Market Segmentation
Figure 12: Classification of Hematologic Malignancies
Figure 13: Global Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 14: Blood Cancer Cases, 2021 (% Share)
Figure 15: Workflow for the Product Approval in the Market
Figure 16: Workflow for the IVD Product Approval
Figure 17: Workflow for Medical Device Regulations
Figure 18: Workflow for Market Approval of In-Vitro Diagnostics in China
Figure 19: COVID-19 Poses Several Concerns for Patients, Health Care Providers, and Health Systems
Figure 20: Global Hematologic Malignancies Testing Market: COVID-19 Impact Analysis
Figure 21: Medical Research Cycle Interruption during the COVID-19 Pandemic
Figure 22: Telemedicine's Potential Advantages
Figure 23: Hematologic Malignancies Testing Supply Chain Analysis
Figure 24: Share of Key Developments and Strategies, January 2018-May 2022
Figure 25: Share of Synergistic Activities (by Company), January 2018-May 2022
Figure 26: Number of Product Launches (by Company), January 2018-May 2022
Figure 27: Share of Product Approval (by Company), January 2018-May 2022
Figure 28: Share of Mergers and Acquisitions (by Company), January 2018-May 2022
Figure 29: Share of other business activities (by Company), January 2018-May 2022
Figure 30: Market Share Analysis of Global Hematologic Malignancies Testing Market (by Company), 2020 and 2021
Figure 31: Growth-Share Analysis for Global Hematologic Malignancies Testing Market (by Platform), 2021
Figure 32: Segmentation of Hematologic Malignancies Testing Market
Figure 33: Share of Global Hematologic Malignancies Market (by Product), $Million, 2021 and 2032
Figure 34: Global Hematologic Malignancies Testing Market (by Kits)
Figure 35: Global Hematologic Malignancies Testing Market (Kits), $Million, 2021-2032
Figure 36: Global Hematologic Malignancies Testing Market (Kits), Thousand Units, 2021-2032
Figure 37: Global Hematologic Malignancies Testing Market (Gene Panels), $Million, 2021-2032
Figure 38: Global Hematologic Malignancies Testing Market (Gene Panels), Thousand Units, 2021-2032
Figure 39: Global Hematologic Malignancies Testing Market (Molecular Clonality Testing), $Million, 2021-2032
Figure 40: Global Hematologic Malignancies Testing Market (Molecular Clonality Testing), Thousand Units, 2021-2032
Figure 41: Company Offering Translocation Panel for Leukemia
Figure 42: Global Hematologic Malignancies Testing Market (Translocation Testing), $Million, 2021-2032
Figure 43: Global Hematologic Malignancies Testing Market (Translocation Testing), Thousand Units, 2021-2032
Figure 44: Companies Offering Mutation Testing Kits
Figure 45: Global Hematologic Malignancies Testing Market (Mutation Testing), $Million, 2021-2032
Figure 46: Global Hematologic Malignancies Testing Market (Mutation testing), Thousand Units, 2021-2032
Figure 47: Global Hematologic Malignancies Testing Market (Minimal Residual Disease (MRD) Testing), $Million, 2021-2032
Figure 48: Global Hematologic Malignancies Testing Market (Minimal Residual Disease (MRD) Testing), Thousand Units, 2021-2032
Figure 49: Global Hematologic Malignancies Testing Market (Services), $Million, 2021-2032
Figure 50: Global Hematologic Malignancies Testing Market (Services), Thousand Units, 2021-2032
Figure 51: Global Hematologic Malignancies Testing Market (by Platform)
Figure 52: Share of Global Hematologic Malignancies Testing Market (by Platform), $Million, 2021 and 2032
Figure 53: Benefits of NGS for Clinical Diagnostics and Biomarker Testing in Oncology
Figure 54: Global Hematologic Malignancies Testing Market (Next-Generation Sequencing (NGS)), $Million, 2021-2032
Figure 55: Global Hematologic Malignancies Testing Market (Next-Generation Sequencing), Thousand Units, 2021-2032
Figure 56: Global Hematologic Malignancies Testing Market (Polymerase Chain Reaction (PCR)), $Million, 2021-2032
Figure 57: Global Hematologic Malignancies Testing Market (Polymerase Chain Reaction (PCR)), Thousand Units, 2021-2032
Figure 58: Global Hematologic Malignancies Testing Market (Fluorescence In-Situ Hybridization (FISH)), $Million, 2021-2032
Figure 59: Global Hematologic Malignancies Testing Market (Fluorescence In-Situ Hybridization (FISH)), Thousand Units, 2021-2032
Figure 60: Global Hematologic Malignancies Testing Market (Immunohistochemistry (IHC)), $Million, 2021-2032
Figure 61: Global hematologic malignancies testing Market (Immunohistochemistry), Thousand Units, 2021-2032
Figure 62: Global Hematologic Malignancies Testing Market (Flow Cytometry), $Million, 2021-2032
Figure 63: Global Hematologic Malignancies Testing Market (Flow Cytometry), Thousand Units, 2021-2032
Figure 64: Global Hematologic Malignancies Testing Market (Other Platforms), $Million, 2021-2032
Figure 65: Global Hematologic Malignancies Testing Market (Other Platforms), Thousand Units, 2021-2032
Figure 66: Share of Global Hematologic Malignancies Testing Market (by Disease), $Million, 2021 and 2032
Figure 67: Global Hematologic Malignancies Testing Market (Leukemia), $Million, 2021-2032
Figure 68: Global Hematologic Malignancies Testing Market (Lymphoma), $Million, 2021-2032
Figure 69: Global Hematologic Malignancies Testing Market (Multiple Myeloma), $Million, 2021-2032
Figure 70: Global Hematologic Malignancies Testing Market (Myeloproliferative Neoplasms), $Million, 2021-2032
Figure 71: Global Hematologic Malignancies Testing Market (Myelodysplastic Syndromes), $Million, 2021-2032
Figure 72: Share of Global Hematologic Malignancies Testing Market (by End User), $Million, 2021 and 2032
Figure 73: Global Hematologic Malignancies Testing Market (Specialty Clinics and Hospitals), $Million, 2021-2032
Figure 74: Global Hematologic Malignancies Testing Market (Specialty Clinics and Hospitals), Thousand Units, 2021-2032
Figure 75: Global Hematologic Malignancies Testing Market (Diagnostic Laboratories), $Million, 2021-2032
Figure 76: Global Hematologic Malignancies Testing Market (Diagnostic Laboratories), Thousand Units, 2021-2032
Figure 77: Global Hematologic Malignancies Testing Market (Reference Laboratories), $Million, 2021-2032
Figure 78: Global Hematologic Malignancies Testing Market (Reference Laboratories), Thousand Units, 2021-2032
Figure 79: Global Hematologic Malignancies Testing Market (Research Institutions), $Million, 2021-2032
Figure 80: Global Hematologic Malignancies Testing Market (Research Institutions), Thousand Units, 2021-2032
Figure 81: Global Hematologic Malignancies Testing Market Snapshot (by Region), $Million, 2021-2032
Figure 82: Global Hematologic Malignancies Testing Market (by Region), $Million, 2021-2032
Figure 83: North America Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 84: North America: Market Dynamics
Figure 85: North America Hematologic Malignancies Testing Market (by Country), $Million, 2021-2032
Figure 86: North America Hematologic Malignancies Testing Market, Thousand Units, 2022-2032
Figure 87: U.S. Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 88: U.S. Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 89: U.S. Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 90: U.S. Hematologic Malignancies Testing Market (by Platform), Thousand Units, 2021, 2025, and 2032
Figure 91: U.S. Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 92: U.S. Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 93: Canada Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 94: Canada Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 95: Canada Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 96: Canada Hematologic Malignancies Testing Market (by Platform), Thousand Units, 2021, 2025, and 2032
Figure 97: Canada Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 98: Canada Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 99: Europe Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 100: Europe Hematologic Malignancies Testing Market (by Country), $Million, 2021-2032
Figure 101: Europe: Market Dynamics
Figure 102: Europe Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 103: Germany Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 104: Germany Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 105: Germany Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 106: Germany Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 107: Germany Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 108: Germany Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 109: France Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 110: France Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 111: France Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 112: France Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 113: France Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 114: France Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 115: U.K. Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 116: U.K. Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 117: U.K. Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 118: U.K. Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 119: U.K. Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 120: U.K. Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 121: Italy Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 122: Italy Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 123: Italy Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 124: Italy Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 125: Italy Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 126: U.S. Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 127: Spain Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 128: Spain Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 129: Spain Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 130: Spain Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 131: Spain Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 132: Spain Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 133: Denmark Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 134: Denmark Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 135: Denmark Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 136: Denmark Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 137: Denmark Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 138: Denmark Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 139: Rest-of-Europe Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 140: Rest-of-Europe Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 141: Rest-of-Europe Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 142: Rest-of-Europe Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 143: Rest-of Europe Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 144: Rest-of-Europe Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 145: Asia-Pacific Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 146: Asia-Pacific Hematologic Malignancies Testing Market (by Country), $Million, 2021-2032
Figure 147: Asia-Pacific: Market Dynamics
Figure 148: Asia-Pacific Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 149: China Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 150: China Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 151: China Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 152: China Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 153: China Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 154: China Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 155: Japan Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 156: Japan Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 157: Japan Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 158: Japan Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 159: Japan Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 160: Japan Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 161: India Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 162: India Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 163: India Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 164: India Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 165: India Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 166: India Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 167: South Korea Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 168: South Korea Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 169: South Korea Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 170: South Korea Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 171: South Korea Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 172: South Korea Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 173: Australia Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 174: Number of Death in Australia by Leukemia (2012-2017)
Figure 175: Australia Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 176: Australia Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 177: Australia Hematologic Malignancies Testing Market (by Platform), Thousand Units, 2021, 2025, and 2032
Figure 178: Australia Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 179: Australia Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 180: Singapore Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 181: Singapore Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 182: Singapore Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 183: Singapore Hematologic Malignancies Testing Market (by Platform), Thousand Units, 2021, 2025, and 2032
Figure 184: Singapore Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 185: Singapore Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 186: Rest-of-Asia-Pacific Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 187: Rest-of-Asia-Pacific Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 188: Rest-of-Asia-Pacific Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 189: Rest-of-Asia-Pacific Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 190: Rest-of-Asia-Pacific Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 191: Rest-of-Asia-Pacific Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 192: Latin America Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 193: Latin America Hematologic Malignancies Testing Market (by Country), $Million, 2021-2032
Figure 194: Latin America: Market Dynamics
Figure 195: Latin America Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 196: Brazil Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 197: Brazil Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 198: Brazil Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 199: Brazil Hematologic Malignancies Testing Market (by Platform), Thousand Units, 2021, 2025, and 2032
Figure 200: Brazil Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 201: Brazil Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 202: Mexico Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 203: Mexico Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 204: Mexico Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 205: Mexico Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 206: Mexico Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 207: Mexico Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 208: Rest-of-Latin America Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 209: Rest-of-Latin America Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 210: Rest-of-Latin America Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 211: Rest-of-Latin America Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 212: Rest-of-Latin America Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 213: Rest-of-Latin America Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 214: Rest-of-the-World Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 215: Rest-of-the-World Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 216: Total Number of Companies Profiled
Figure 217: Abbott.: Overall Product Portfolio
Figure 218: Abbott.: Overall Financials, $Million, 2019-2021
Figure 219: Abbott.: Revenue (by Segment), $Million, 2019-2021
Figure 220: Abbott.: Revenue (by Region), $Million, 2019-2021
Figure 221: Abbott.: R&D Expenditure, $Million, 2019-2021
Figure 222: ASURAGEN, INC.: Overall Product Portfolio
Figure 223: Adaptive Biotechnologies: Overall Product Portfolio
Figure 224: Adaptive Biotechnologies: Overall Financials, $Million, 2019-2021
Figure 225: Adaptive Biotechnologies: Revenue (by Segment), $Million, 2019-2021
Figure 226: Adaptive Biotechnologies: R&D Expenditure, $Million, 2019-2021
Figure 227: ARUP Laboratories: Overall Product Portfolio
Figure 228: Bio-Rad Laboratories, Inc.: Overall Product Portfolio
Figure 229: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
Figure 230: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 231: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 232: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 233: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 234: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
Figure 235: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2019-2021
Figure 236: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2019-2021
Figure 237: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
Figure 238: Illumina, Inc.: Overall Product Portfolio
Figure 239: Illumina, Inc.: Overall Financials, $Million, 2019-2021
Figure 240: Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 241: Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 242: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 243: ICON plc: Overall Product Portfolio
Figure 244: ICON plc: Overall Financials, $Million, 2019-2021
Figure 245: ICON plc: Revenue (by Region), $Million, 2019-2021
Figure 246: Invivoscribe, Inc.: Overall Product Portfolio
Figure 247: Invitae Corporation.: Overall Product Portfolio
Figure 248: Invitae Corporation.: Overall Financials, $Million, 2019-2021
Figure 249: Invitae Corporation.: Revenue (by Segment), $Million, 2019-2021
Figure 250: Invitae Corporation.: Revenue (by Region), $Million, 2019-2021
Figure 251: Invitae Corporation.: R&D Expenditure, $Million, 2019-2021
Figure 252: Laboratory Corporation of America Holdings: Overall Product Portfolio
Figure 253: Laboratory Corporation of America Holdings: Overall Financials, $Million, 2019-2021
Figure 254: Laboratory Corporation of America Holdings: Revenue (by Segment), $Million, 2019-2021
Figure 255: Laboratory Corporation of America Holdings: Revenue (by Region), $Million, 2019-2021
Figure 256: NeoGenomics Laboratories: Overall Product Portfolio
Figure 257: NeoGenomics Laboratories: Overall Financials, $Million, 2019-2021
Figure 258: NeoGenomics Laboratories: Revenue (by Segment), $Million, 2019-2021
Figure 259: NeoGenomics Laboratories: R&D Expenditure, $Million, 2019-2021
Figure 260: OHSU’s Knight Diagnostic Laboratories: Overall Product Portfolio
Figure 261: Precipio: Overall Product Portfolio
Figure 262: Precipio: Overall Financials, $Million, 2019-2021
Figure 263: Precipio: Revenue (by Segment), $Million, 2019-2021
Figure 264: QIAGEN N.V.: Overall Product Portfolio
Figure 265: QIAGEN N.V.: Overall Financials, $Million, 2019-2021
Figure 266: QIAGEN N.V.: Revenue (by Segment), $Million, 2019-2021
Figure 267: QIAGEN N.V.: Revenue (by Region), $Million, 2019-2021
Figure 268: QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021
Figure 269: Quest Diagnostics: Overall Product Portfolio
Figure 270: Quest Diagnostics: Overall Financials, $Million, 2019-2021
Figure 271: Quest Diagnostics: Revenue (by Segment), $Million, 2019-2021
Figure 272: Sysmex Corporation: Overall Product Portfolio
Figure 273: Sysmex Corporation: Overall Financials, $Million, 2018-2020
Figure 274: Sysmex Corporation: Revenue (by Segment), $Million, 2018-2020
Figure 275: Sysmex Corporation: Revenue (by Region), $Million, 2018-2020
Figure 276: Sysmex Corporation: R&D Expenditure, $Million, 2018-2020
List of Tables
Table 1: Diagnostic Tests for Hematologic Malignancies
Table 2: Likert Scale
Table 3: Impact Analysis of Market Drivers
Table 4: Impact Analysis of Market Restraints
Table 5: Registration Criteria for IVDs as per the CFDA
Table 6: Effect of COVID-19 on Cancer Care Throughout the World
Table 7: Companies Offering Gene Panels
Table 8: Companies Offering Services
Table 9: NGS-Based Products
Table 10: PCR-Based Products
Table 11: Companies Offering FISH-Based Products
Table 12: Companies Offering IHC-Based Products
Table 13: Company Offering Flow Cytometry-Based Product
Table 14: Estimated Cases of Leukemia, by Gender, 2021
Table 15: Companies Offering Leukemia Testing Products
Table 16: Estimated Cases of Lymphoma, by Gender, 2021
Table 17: Companies Offering Lymphoma Testing Products
Table 18: Estimated Cases of Myeloma, by Gender, 2021
Table 19: Companies Offering Multiple Myeloma Products